BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23502221)

  • 1. Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.
    Nganga VK; Palmer VL; Naushad H; Kassmeier MD; Anderson DK; Perry GA; Schabla NM; Swanson PC
    Blood; 2013 May; 121(19):3855-66, S1-16. PubMed ID: 23502221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.
    Lascano V; Guadagnoli M; Schot JG; Luijks DM; Guikema JE; Cameron K; Hahne M; Pals S; Slinger E; Kipps TJ; van Oers MH; Eldering E; Medema JP; Kater AP
    Blood; 2013 Dec; 122(24):3960-3. PubMed ID: 24100449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia.
    Müller DJ; Wirths S; Fuchs AR; Märklin M; Heitmann JS; Sturm M; Haap M; Kirschniak A; Sasaki Y; Kanz L; Kopp HG; Müller MR
    J Leukoc Biol; 2019 Mar; 105(3):531-538. PubMed ID: 30556925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
    Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
    Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
    Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
    Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
    Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
    Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
    Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia.
    Röder B; Fahnenstiel H; Schäfer S; Budeus B; Dampmann M; Eichhorn M; Angermüller S; Brost C; Winkler TH; Seifert M; Nitschke L
    EMBO Rep; 2023 Aug; 24(8):e56420. PubMed ID: 37424400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cd1d regulates B cell development but not B cell accumulation and IL10 production in mice with pathologic CD5(+) B cell expansion.
    Palmer VL; Nganga VK; Rothermund ME; Perry GA; Swanson PC
    BMC Immunol; 2015 Nov; 16():66. PubMed ID: 26537916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.
    Enzler T; Kater AP; Zhang W; Widhopf GF; Chuang HY; Lee J; Avery E; Croce CM; Karin M; Kipps TJ
    Blood; 2009 Nov; 114(20):4469-76. PubMed ID: 19755673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
    Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A
    Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of B1-like B cells in transgenic mice over-expressing catalytically inactive RAG1 in the periphery.
    Hassaballa AE; Palmer VL; Anderson DK; Kassmeier MD; Nganga VK; Parks KW; Volkmer DL; Perry GA; Swanson PC
    Immunology; 2011 Dec; 134(4):469-86. PubMed ID: 22044391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
    Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.
    Iacovelli S; Hug E; Bennardo S; Duehren-von Minden M; Gobessi S; Rinaldi A; Suljagic M; Bilbao D; Bolasco G; Eckl-Dorna J; Niederberger V; Autore F; Sica S; Laurenti L; Wang H; Cornall RJ; Clarke SH; Croce CM; Bertoni F; Jumaa H; Efremov DG
    Blood; 2015 Mar; 125(10):1578-88. PubMed ID: 25564405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD74 is dispensable for development of chronic lymphocytic leukemia in
    Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
    Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
    Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
    Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is miR-29 an oncogene or tumor suppressor in CLL?
    Pekarsky Y; Croce CM
    Oncotarget; 2010 Jul; 1(3):224-7. PubMed ID: 20936047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling.
    Chen SS; Batliwalla F; Holodick NE; Yan XJ; Yancopoulos S; Croce CM; Rothstein TL; Chiorazzi N
    Proc Natl Acad Sci U S A; 2013 Apr; 110(16):E1500-7. PubMed ID: 23550156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early generated B1 B cells with restricted BCRs become chronic lymphocytic leukemia with continued c-Myc and low Bmf expression.
    Hayakawa K; Formica AM; Brill-Dashoff J; Shinton SA; Ichikawa D; Zhou Y; Morse HC; Hardy RR
    J Exp Med; 2016 Dec; 213(13):3007-3024. PubMed ID: 27899442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.